読み込み中
Silence Therapeutics plc is a London, UK-based biotechnology company specializing in the research and development of groundbreaking ribonucleic acid (RNA) therapeutics. Its therapeutic focus areas include hematological, cardiovascular, and various rare and metabolic conditions. Central to their innovative approach is the mRNAi GalNAc Oligonucleotide Discovery platform, which is designed for precise targeting of specific disease-causing genes within the liver. The company's methodology harnesses the body's natural RNA interference (RNAi) mechanism by designing short interfering RNA (siRNA) molecules that degrade messenger RNA (mRNA), thereby preventing the production of targeted disease-associated proteins. Their pipeline features several promising candidates, including SLN360, currently in Phase I clinical trials for cardiovascular disease associated with elevated lipoprotein. Another key candidate, SLN124, is undergoing Phase I clinical trials for non-transfusion-dependent thalassemia and myelodysplastic syndrome, with further development planned for polycythemia vera. Silence Therapeutics also engages in strategic collaborations to expand its reach. It has agreements with AstraZeneca PLC to discover, develop, and commercialize siRNA therapeutics for cardiovascular, renal, metabolic, and respiratory diseases. Furthermore, a partnership with Mallinckrodt Pharma IP Trading DAC aims to develop and commercialize RNAi drug targets designed to silence the complement cascade in complement-mediated disorders. The company is also collaborating with Hansoh Pharmaceutical Group Company Limited to develop siRNAs for three unspecified targets, utilizing Silence's mRNAi GOLD platform. Originally incorporated as SR Pharma plc, the company rebranded to Silence Therapeutics plc in May 2007.
通常取引
$10.22
+$0.70 · +7.35%
日中の時刻はETです。市場データは遅延する場合があります。
Silence Therapeutics plc is a London, UK-based biotechnology company specializing in the research and development of groundbreaking ribonucleic acid (RNA) therapeutics. Its therapeutic focus areas include hematological, cardiovascular, and various rare and metabolic conditions. Central to their innovative approach is the mRNAi GalNAc Oligonucleotide Discovery platform, which is designed for precise targeting of specific disease-causing genes within the liver. The company's methodology harnesses the body's natural RNA interference (RNAi) mechanism by designing short interfering RNA (siRNA) molecules that degrade messenger RNA (mRNA), thereby preventing the production of targeted disease-associated proteins. Their pipeline features several promising candidates, including SLN360, currently in Phase I clinical trials for cardiovascular disease associated with elevated lipoprotein. Another key candidate, SLN124, is undergoing Phase I clinical trials for non-transfusion-dependent thalassemia and myelodysplastic syndrome, with further development planned for polycythemia vera. Silence Therapeutics also engages in strategic collaborations to expand its reach. It has agreements with AstraZeneca PLC to discover, develop, and commercialize siRNA therapeutics for cardiovascular, renal, metabolic, and respiratory diseases. Furthermore, a partnership with Mallinckrodt Pharma IP Trading DAC aims to develop and commercialize RNAi drug targets designed to silence the complement cascade in complement-mediated disorders. The company is also collaborating with Hansoh Pharmaceutical Group Company Limited to develop siRNAs for three unspecified targets, utilizing Silence's mRNAi GOLD platform. Originally incorporated as SR Pharma plc, the company rebranded to Silence Therapeutics plc in May 2007.
日中レンジ
現在 $10.22
52週レンジ
現在 $10.22
日中の時刻はETです。市場データは遅延する場合があります。
GoAI スコア
売り
バリュエーション
21
割高
センチメント
45
まちまち
リスク
56
やや高いリスク
モメンタム
70
上昇基調
GoAIの詳細リサーチ
詳しい根拠、カタリスト、リスクを確認できます。
Silence Therapeutics plc is a London, UK-based biotechnology company specializing in the research and development of groundbreaking ribonucleic acid (RNA) therapeutics. Its therapeutic focus areas include hematological, cardiovascular, and various rare and metabolic conditions. Central to their innovative approach is the mRNAi GalNAc Oligonucleotide Discovery platform, which is designed for precise targeting of specific disease-causing genes within the liver. The company's methodology harnesses the body's natural RNA interference (RNAi) mechanism by designing short interfering RNA (siRNA) molecules that degrade messenger RNA (mRNA), thereby preventing the production of targeted disease-associated proteins. Their pipeline features several promising candidates, including SLN360, currently in Phase I clinical trials for cardiovascular disease associated with elevated lipoprotein. Another key candidate, SLN124, is undergoing Phase I clinical trials for non-transfusion-dependent thalassemia and myelodysplastic syndrome, with further development planned for polycythemia vera. Silence Therapeutics also engages in strategic collaborations to expand its reach. It has agreements with AstraZeneca PLC to discover, develop, and commercialize siRNA therapeutics for cardiovascular, renal, metabolic, and respiratory diseases. Furthermore, a partnership with Mallinckrodt Pharma IP Trading DAC aims to develop and commercialize RNAi drug targets designed to silence the complement cascade in complement-mediated disorders. The company is also collaborating with Hansoh Pharmaceutical Group Company Limited to develop siRNAs for three unspecified targets, utilizing Silence's mRNAi GOLD platform. Originally incorporated as SR Pharma plc, the company rebranded to Silence Therapeutics plc in May 2007.
日中レンジ
現在 $10.22
52週レンジ
現在 $10.22
利用可能な期間全体で報告されたマージン。
売上高
営業利益
純利益
| 指標（USD） | 2025年度 | 2024年度 | 2023年度 | 2022年度 | 2021年度 |
|---|---|---|---|---|---|
| 売上高 | 55.9万 USD | 4325.8万 USD | 2537.5万 USD | 1765.3万 USD | 1241.5万 USD |
| 売上原価 | 21.5万 USD | 1181万 USD | 1031.8万 USD | 1097.5万 USD | 745.6万 USD |
| 粗利益 | 34.4万 USD | 3144.8万 USD | 1505.7万 USD | 667.81万 USD | 495.9万 USD |
| 研究開発 | 6775.3万 USD | 6788.3万 USD | 4402.5万 USD | 3550.17万 USD | 3076.5万 USD |
| 販売・一般管理 | 2234.4万 USD | 2688.4万 USD | 2063.6万 USD | 2093.58万 USD | 2000.8万 USD |
| 営業費用 | 9009.7万 USD | 9476.7万 USD | 6466.1万 USD | 5643.76万 USD | 5077.3万 USD |
| 受取利息 | 348万 USD | 447.2万 USD | 144.6万 USD | 22.6万 USD | 1万 USD |
| 支払利息 | — | — | 3.4万 USD | 4.7万 USD | 8000 USD |
| 減価償却費と償却費 | 55.5万 USD | 46.33万 USD | 49.8万 USD | 49.09万 USD | 42.51万 USD |
| 営業利益 | −8975.3万 USD | −6331.9万 USD | −4960.4万 USD | −4975.95万 USD | −4581.4万 USD |
| 純利益 | −8861.2万 USD | −4530.9万 USD | −4326.7万 USD | −4103.2万 USD | −3941万 USD |
会社概要が更新されました 2026年10月9日.
直近の発表実績
直近の発表実績
第三者のアナリスト予想は変更される場合があり、GoAIの推奨ではありません。
この株式へのエクスポージャーを報告している上場投資信託です。
iShares Biotechnology ETFIBB274.22万0.03%104.14億 USD0.44%$206.47+2.99%
State Street SPDR S&P International Small Cap ETFGWX20.98万0.02%9.18億 USD0.40%$45.56+0.93%
ActivePassive International Equity ETFAPIE10.3万0.01%11.33億 USD0.45%$38.5236+0.56%
Invesco Nasdaq Biotechnology ETFIBBQ3.37万0.03%1.09億 USD0.19%$34.60+2.90%
ProShares Ultra Nasdaq BiotechnologyBIB1.58万0.02%8827.36万 USD1.19%$110.85+5.55%iShares Biotechnology ETFIBBState Street SPDR S&P International Small Cap ETFGWXActivePassive International Equity ETFAPIEInvesco Nasdaq Biotechnology ETFIBBQProShares Ultra Nasdaq BiotechnologyBIBAIが生成した遅延市場データを、情報提供および教育目的で掲載しています。投資助言ではありません。
